or Try an Advanced Search...

    Technical Analysis for CARA - Cara Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 0.31 1.36% 0.00
    CARA closed up 1.36 percent on Wednesday, November 20, 2024, on 38 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Down
    Historical CARA trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    20 DMA Resistance Bearish 1.36%
    50 DMA Support Bullish 1.36%
    Outside Day Range Expansion 1.36%
    Wide Bands Range Expansion 1.36%
    Fell Below 20 DMA Bearish 4.27%
    Older End-of-Day Signals for CARA ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 18 hours ago
    Possible Inside Day about 18 hours ago
    60 Minute Opening Range Breakout about 21 hours ago
    Rose Above 20 DMA about 22 hours ago
    20 DMA Resistance about 22 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CARA Chart by TradingView
    Basic chart:

    Profile

    Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Pain Clinical Trial Chronic Pain Amines Acute And Chronic Pain Piperidines Mesoblast

    Is CARA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 17 Cara Therapeutics Third Quarter 2024 Earnings: Beats Expectations
    Nov 15 Cara: Q3 Earnings Snapshot
    Nov 1 Cannabis Stock Gainers And Losers From November 1, 2024
    Oct 31 Cannabis Stock Gainers And Losers From October 31, 2024
    Sep 18 Bullish Wednesday For Marijuana Stocks - Australis Capital, Leafbuyer Techs Among Top Gainers
    Sep 11 Cannabis Stock Movers For September 11, 2024
    Aug 20 Marijuana Stock Movers For August 20, 2024
    Aug 16 Bullish Friday For Marijuana Stocks - Australis Capital, Green Growth Brands Among Top Gainers
    Aug 15 Cara: Q2 Earnings Snapshot
    Jul 26 Bullish Friday For Marijuana Stocks - GreenGro Technologies, Leafbuyer Techs Among Top Gainers
    See more CARA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.31
    52 Week Low 0.24
    Average Volume 543,142
    200-Day Moving Average 0.51
    50-Day Moving Average 0.29
    20-Day Moving Average 0.30
    10-Day Moving Average 0.32
    Average True Range 0.03
    RSI (14) 51.46
    ADX 27.34
    +DI 15.79
    -DI 15.34
    Chandelier Exit (Long, 3 ATRs) 0.29
    Chandelier Exit (Short, 3 ATRs) 0.33
    Upper Bollinger Bands 0.36
    Lower Bollinger Band 0.25
    Percent B (%b) 0.51
    BandWidth 34.62
    MACD Line 0.01
    MACD Signal Line 0.01
    MACD Histogram -0.002
    Fundamentals Value
    Market Cap 16.62 Million
    Num Shares 54.5 Million
    EPS -2.15
    Price-to-Earnings (P/E) Ratio -0.14
    Price-to-Sales 1.45
    Price-to-Book 0.37
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.33
    Resistance 3 (R3) 0.33 0.32 0.32
    Resistance 2 (R2) 0.32 0.32 0.32 0.32
    Resistance 1 (R1) 0.31 0.31 0.32 0.31 0.32
    Pivot Point 0.31 0.31 0.31 0.31 0.31
    Support 1 (S1) 0.30 0.30 0.30 0.30 0.29
    Support 2 (S2) 0.29 0.30 0.29 0.29
    Support 3 (S3) 0.28 0.29 0.29
    Support 4 (S4) 0.28